Loading...
XSTO
VIVE
Market cap7mUSD
Dec 05, Last price  
0.13SEK
1D
0.15%
1Q
-43.57%
Jan 2017
-97.72%
IPO
-99.15%
Name

Vivesto AB

Chart & Performance

D1W1MN
XSTO:VIVE chart
P/E
—
P/S
107.66
EPS
—
Div Yield, %
—
Shrs. gr., 5y
12.88%
Rev. gr., 5y
27.27%
Revenues
656k
+553.74%
11853,22222,387,00071,158,00079,357,00030,741,000106,000891,000060,0002,070,0006,373,000172,0003,169,0001,980,000201,843,000201,843,00026,192,000100,297655,686
Net income
-12m
L-65.60%
2,505,381-7,306,969-9,757,000-5,067,000-7,105,000-17,054,000-65,960,000-65,670,000-72,381,000-105,112,000-117,497,000-141,539,000-160,243,000-118,007,000-171,020,000-10,533,000-10,533,000-138,945,000-35,249,284-12,127,042
CFO
-6m
L-18.61%
6,529,528-11,270,940-22,735,0009,00014,276,000-11,235,000-57,598,000-52,439,000-69,539,000-86,899,000-107,665,000-128,126,000-133,011,000-123,634,000-118,839,000-6,866,000-204,862,500-145,565,000-7,956,309-6,475,354

Notes

No notes on this company yet
Write a private note on this company, for your eyes only
Add note

Profile

Vivesto AB develops, produces, markets, and sells drugs in the field of human and veterinary oncology primarily in Sweden. Its lead product is Apealea (paclitaxel micellar) for the treatment of ovarian cancer. The company's products portfolio includes Docetaxel micellar, a patented formulation that combines cytotoxin docetaxel with XR-17, which is in Phase 1b clinical trial for the treatment of prostate cancer; and Cantrixil to treat ovarian cancer. its animal health product portfolio includes Paccal Vet, a formulation of paclitaxel with its XR-17 encapsulation technology for the treatment of canine mastocytoma; and Doxophos Vet, a patented formulation of doxorubicin to treat lymphoma. The company was formerly known as Oasmia Pharmaceutical AB (publ) and changed its name to Vivesto AB in March 2022. Vivesto AB was incorporated in 1988 and is headquartered in Solna, Sweden.
URL
https://www.vivesto.com/
IPO date
Jan 01, 2005
Employees
19
Domiciled in
SE
Incorporated in
SE

Valuation

Title
SEK in thousands, except ratios and share amounts
FYFYFYFYFYFYFYFYFYFY
2023‑122022‑122021‑122020‑122020‑102020‑042019‑042018‑042017‑042016‑04
Income
Revenues
Cost of revenue
Unusual Expense (Income)
NOPBT
NOPBT Margin
Operating Taxes
Tax Rate
NOPAT
Net income
Dividends
Dividend yield
Proceeds from repurchase of equity
BB yield
Debt
Debt current
Long-term debt
Deferred revenue
Other long-term liabilities
Net debt
Cash flow
Cash from operating activities
CAPEX
Cash from investing activities
Cash from financing activities
FCF
Balance
Cash
Long term investments
Excess cash
Stockholders' equity
Invested Capital
ROIC
ROCE
EV
Common stock shares outstanding
Price
Market cap
EV
EBITDA
EV/EBITDA
Interest
Interest/NOPBT